The patient journey: Time to look beyond the physician?
Treatment initiation is a key focus for many pharma companies as part of their strategy to increase script writing and drive greater revenues.
However a recent study demonstrated that physicians spend as little as 49 seconds in dealing with a new treatment initiation with their patients.
So it is no surprise that more and more pharma marketers are steadily looking beyond the physician in order to improve patient engagement.
In this webinar Director Katrina Johnson and Associate Director Kate Hanson explore the ways that patient journey research can aid development of an effective "beyond the pill" strategy, leading to greater patient engagement and improved treatment outcomes.
5 years on from the Brazilian Generics Drugs Act, is there still an opportunity for branded originator drugs?
Published in eyeforpharma 10 November by Paul Reed
In 2009 the Brazilian government passed the Generics Drugs Act; one of numerous initiatives intended to reduce spend on originator branded drugs, whilst boosting generic drug prescription and supporting the domestic drug industry.
5 years on from the act, how successful have the Brazilian government been in advancing the local pharmaceutical players while reducing branded originator drugs spend? And importantly, is there still an opportunity for branded originator drugs?
Exploring HCV in Brazil
Brazil has developed a strong commitment to universal access to healthcare and now promotes a “health for all” vision that is providing more advanced treatments to a whole new class of patient.
This has caused the healthcare challenges to shift from a lack of availability, to discussions about willingness to spend limited resources and effective allocation of treatment. All of which has led to Brazil becoming one of the world’s largest pharma markets.
The American College of Rheumatology 2014 Annual Meeting
Join us at ACR’s 2014 Annual Meeting in Boston on November 18th
We are delighted to be presenting a poster at the American College of Rheumatology’s 2014 Annual Meeting, which is set to take place in Boston, 14th to 19th November. It is a key meeting in the field of rheumatology providing physicians with a wide range of educational programs in every area of the field, including our poster presentation on "Early Treatment in Rheumatoid Arthritis and Its Effect on Patient Outcomes".
Physicians predict the impact new molecules will have on the EU psoriasis market
With several new molecules expected to launch onto the psoriasis market over the next 12 months, we recently asked our panel of 200 EU-based dermatologists the impact this may have on their future prescribing behaviour.
Utilising our panel of 200 EU based dermatologists, our results reveal that 74% of physicians are aware of new classes and/or drugs in development for the treatment of Psoriasis (PsO) without prompting. IL-17 inhibitors were the most commonly mentioned drugs cited by 75% of respondents, followed by JAK-inhibitors and PDE-inhibitors. However, when physicians were prompted about their familiarity with key pipeline agents they reported low scores overall, suggesting that more awareness and improvement of physicians’ knowledge of these late stage compounds are needed to achieve growth in the market.